Clinical Trials

Phase 1/2 Not yet recruiting

Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07398638 2026-02-10

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

122 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07272499 2025-12-09

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Phase 2 Recruiting

25 enrolled

Lymphoma, Mantle-Cell

NCT07255963 2025-12-01

Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL

Phase 2 Recruiting

29 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT06389292 2025-11-25

A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia

Phase 3 Recruiting

486 enrolled

Leukemia, Myeloid, Acute

NCT04496349 2025-11-04

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

Phase 2 Recruiting

78 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Prolymphocytic, T-Cell

NCT04501120 2025-09-26

Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML

Phase 1/2 Recruiting

458 enrolled

Phase 1/2 Not yet recruiting

Leukemia, Myeloid, Acute

NCT07159906 2025-09-08

Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

62 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04260217 2025-08-19

MAPLE-1

Phase 1 Completed

46 enrolled

Phase 1 Active not recruiting

Waldenstrom Macroglobulinemia

NCT03913949 2025-04-16

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

74 enrolled

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04494503 2025-04-16

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Phase 1/2 Recruiting

123 enrolled

Phase EARLY_PHASE1 Recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05701306 2025-02-25

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Phase 1 Recruiting

100 enrolled

CNS

Neuroblastoma

NCT03537482 2024-08-19

APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

90 enrolled

Hematologic Neoplasms

NCT04946864 2024-08-19

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Phase 1/2 Suspended

65 enrolled

Breast

Breast Neoplasms

NCT04942067 2023-10-25

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

108 enrolled

Plasma cell

Amyloidosis, Multiple Myeloma

NCT04964518 2023-10-25

A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML)

Phase 1/2 Unknown

24 enrolled

Leukemia, Myeloid, Acute

NCT04674514 2023-03-07

APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

48 enrolled

Plasma cell

Multiple Myeloma

NCT05495035 2023-03-02

Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL

Phase 1 Unknown

22 enrolled